Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects

por Flamme, Ingo, Oehme, Felix, Ellinghaus, Peter, Jeske, Mario, Keldenich, Jörg, Thuss, Uwe
Publicado 2014

First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics

por Klein, Stefan, Gashaw, Isabella, Baumann, Sybille, Chang, Xinying, Hummel, Thomas, Thuß, Uwe, Friedrich, Christian
Publicado 2022

Absorption, distribution, metabolism and excretion of molidustat in healthy participants

por Lentini, Silvia, van der Mey, Dorina, Kern, Armin, Thuss, Uwe, Kaiser, Andreas, Matsuno, Kumi, Gerisch, Michael
Publicado 2020

Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia

por Beck, Hartmut, Jeske, Mario, Thede, Kai, Stoll, Friederike, Flamme, Ingo, Akbaba, Metin, Ergüden, Jens‐Kerim, Karig, Gunter, Keldenich, Jörg, Oehme, Felix, Militzer, Hans‐Christian, Hartung, Ingo V., Thuss, Uwe
Publicado 2018

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

por Grünewald, Sylvia, Politz, Oliver, Bender, Sebastian, Héroult, Mélanie, Lustig, Klemens, Thuss, Uwe, Kneip, Christoph, Kopitz, Charlotte, Zopf, Dieter, Collin, Marie‐Pierre, Boemer, Ulf, Ince, Stuart, Ellinghaus, Peter, Mumberg, Dominik, Hess‐Stumpp, Holger, Ziegelbauer, Karl
Publicado 2019